

Timothy Charles Hlavinka, M.D.
Urology San Antonio
7909 Fredericksburg Road Suite 135
San Antonio, Texas 78229

EDUCATION:

1973-1977	Texas A&M University College Station, Texas Bachelors of Arts Degree
1980-1984	University of Texas Medical Branch Galveston, Texas Doctorate of Medicine Degree
1984 – 1985	University of Texas Health Science Center San Antonio, Texas Internship
1985 – 1986	University of Texas Health Science Center San Antonio, Texas Residency
1986 – 1991	University of Texas Health Science Center San Antonio, Texas Residency

WORK EXPERIENCE:

1991 – Present	Urology San Antonio, P.A. 7909 Fredericksburg Rd. Suite 200, 135 San Antonio, Texas 78229 Group Practice-Urologist
1996 – Present	Urology San Antonio Research, PA San Antonio, Texas Investigator
2005 - Present	Urology San Antonio for Female Sexual Medicine 7909 Fredericksburg Rd. Suite 210 San Antonio, Texas 78229 Co-Director

CREDENTIALS:

1993	Diplomate American Board of Urology
------	-------------------------------------

HOSPITAL AFFILIATIONS:

- 1994 – Present Baptist Healthcare Systems
 San Antonio, Texas
 Medical Staff Member

- 1996 – Present Christus Santa Rosa Healthcare Systems
 San Antonio, Texas
 Medical Staff Member

- 1992 – Present Methodist Healthcare Systems
 San Antonio, Texas
 Medical Staff Member

PROFESSIONAL AFFILIATIONS:

- American Medical Association

- Texas Medical Association

- Bexar County Medical Society

PUBLICATIONS:

1. Epstein, A., Hlavinka, T.C., Novicki, E.E. Computerized Tomography of Spontaneous Forniceal Extravastation, “Urology,” Vol. 33:344 – 345.

2. Nutrition in Clinical Practice, “Ford, E.G., Jennings, L.M., Hlavinka, T.C., Andrasy, R.J: Feeding Catheter Jejunostomy in Neonates with Proximal Gastrointestinal Dysfunction.” Chapter 3: 106 – 107.

3. King, H.C., Hlavinka, T.C., Sarosdy, M.F. Additional Experience with Continent Urinary Diversion Using Cutaneous Ileocecostoplasty. “Urology,” Vol. 47 (4), 1996.

ABSTRACTS:

1. Hlavinka, T.C., Neal, D., Jr., Rodriguez, F.R., Pettsman, S., and Novicki, D.E. External Beam Radiation and Stage C Prostate Cancer. Boston, Massachusetts “83rd Annual Mtg. Of the American Urological Assoc.” Page 470A, 1988.

CLINICAL RESEARCH EXPERIENCE:

1. “Open – Label Study Of The Efficacy And Safety Of An Aqueous XXXXX Topical Cream In The Treatment Of Erectile Dysfunction.”

2. “Phase III, Efficacy and Safety of An Aqueous XXXXX Topical Cream In The Treatment Of Erectile Dysfunction.”

3. “A Multicenter, Randomized, Placebo Controlled, Two Period (Clinic, Home) Efficacy and Safety Study Of Intraurethral Administered XXXXX In The Treatment Of Mild To Moderate Erectile Dysfunction.”
4. “A Phase II, Safety Study of 5 mg. XXXXX Versus Placebo In The Treatment Of Patients Diagnosed With Male Erectile Dysfunction Following A Bilateral Nerve – Sparing Radical Retropubic Prostatectomy.”
5. “A Phase III Efficacy And Safety Study Of Three Fixed Doses Of XXXXX SL Tablets 2, 4, and 5 mg. Versus Placebo In The Treatment Of Male Erectile Dysfunction.”
6. “A Randomized, Double – Blind, Multicenter, Phase III Study Of XXXXX And XXXXX In The Treatment Of Chronic Bacterial Prostatitis.”
7. “A Randomized, Double – Blind, Placebo Controlled, Multicenter, Comparative, Safety And Efficacy Study Of Intravenous XXXXX In Prostate Cancer Subjects With Metastatic Bone Lesions Receiving Antineoplastic Therapy.”
8. “A Multi-center Study Of XXXXX In Patients With Prostate Cancer In Whom GnRH Agonists Are Contraindicated.”
9. “A Phase III, Multicenter, Open – Label, Randomized Study Of XXXXX VS. XXXXX, In Patients with Prostate Cancer Who Are Candidates For Initial.”
10. “A Phase III, Multicenter, Open – Label Study Of XXXXX To Achieve Prostate Gland Volume Reduction In Patients With Prostate Cancer Prior To Definitive Local Therapy.”
11. “A Dose Escalating, Single – Blind, Placebo Controlled Clinical Trial Evaluating The Safety, Tolerance And Effects Of XXXXX.”
12. “A Phase III, open-label, multi-center study of the efficacy and safety of XXXXX in the treatment of Patients with non-muscle invasive (superficial) bladder cancer at high risk of progression and who are refractory to BCG.”
13. “A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Repeat Treatment with Two Dose Levels of XXXXX (XXXXX) XXXXX Followed by a Treatment with XXXXX in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity.”
14. “A Twenty Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trail of XXXXX 50 milligrams Daily and, with Uptitration, 100 Milligrams Daily in Premenopausal Women with Hypoactive Sexual Desire Disorder.”
15. “Pilot Study of the Intervesimal Administration of XXXXX Immediately Following Transurethral Resection in Patients with Superficial Bladder Cancer.”